Pacer Advisors Inc. Sells 714,501 Shares of IQVIA Holdings Inc. $IQV

Pacer Advisors Inc. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 98.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,997 shares of the medical research company’s stock after selling 714,501 shares during the quarter. Pacer Advisors Inc.’s holdings in IQVIA were worth $3,155,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Dana Investment Advisors Inc. raised its stake in shares of IQVIA by 18.4% during the 3rd quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company’s stock worth $30,401,000 after acquiring an additional 24,854 shares in the last quarter. Strive Asset Management LLC acquired a new stake in IQVIA in the third quarter valued at approximately $17,447,000. Picton Mahoney Asset Management grew its holdings in IQVIA by 3,086.9% in the third quarter. Picton Mahoney Asset Management now owns 48,824 shares of the medical research company’s stock worth $9,275,000 after purchasing an additional 47,292 shares during the last quarter. WINTON GROUP Ltd purchased a new position in IQVIA in the third quarter worth $3,383,000. Finally, Artisan Partners Limited Partnership increased its position in shares of IQVIA by 4.9% during the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after purchasing an additional 161,085 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Royal Bank Of Canada began coverage on IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target for the company. Morgan Stanley restated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Stock Performance

Shares of IQV opened at $171.21 on Wednesday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a 50-day moving average of $173.68 and a two-hundred day moving average of $190.61. The stock has a market cap of $28.57 billion, a P/E ratio of 21.22, a P/E/G ratio of 1.44 and a beta of 1.21. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the prior year, the company earned $2.70 earnings per share. The company’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its board has approved a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.